Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

被引：28

作者：

Sonpavde, G. ^{[2
]}

Choueiri, T. K. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02215 USA

[2] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 07期

关键词：

renal cell carcinoma; biomarkers; prognostic; predictive; ENDOTHELIAL GROWTH-FACTOR; SINGLE NUCLEOTIDE POLYMORPHISMS; CARBONIC-ANHYDRASE-IX; INTERFERON-ALPHA; EFFICACY; SUNITINIB; SORAFENIB; CANCER; TEMSIROLIMUS; PREDICTORS;

D O I：

10.1038/bjc.2012.399

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents. British Journal of Cancer (2012) 107, 1009-1016. doi:10.1038/bjc.2012.399 www.bjcancer.com Published online 4 September 2012 (c) 2012 Cancer Research UK

引用

页码：1009 / 1016

页数：8

共 56 条

[11] von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma [J].

Choueiri, Toni K. ;

Vaziri, Susan A. J. ;

Jaeger, Erich ;

Elson, Paul ;

Wood, Laura ;

Bhalla, Ish Prasad ;

Small, Eric J. ;

Weinberg, Vivian ;

Sein, Nancy ;

Simko, Jeff ;

Golshayan, Ali-Reza ;

Sercia, Linda ;

Zhou, Ming ;

Waldman, Frederic M. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Ganapathi, Ram .

JOURNAL OF UROLOGY, 2008, 180 (03) :860-865

[12]

Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223

[13] Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy [J].

Choueiri, Toni K. ;

Regan, Meredith M. ;

Rosenberg, Jonathan E. ;

Oh, William K. ;

Clement, Jessica ;

Amato, Angela M. ;

McDermott, David ;

Cho, Daniel C. ;

Atkins, Michael B. ;

Signoretti, Sabina .

BJU INTERNATIONAL, 2010, 106 (06) :772-778

[14] Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome. [J].

Dabydeen, D. A. ;

Jagannathan, J. P. ;

Ramaiya, N. H. ;

Krajewski, K. M. ;

Schutz, F. A. B. ;

Cho, D. C. ;

Pedrosa, I. ;

Choueiri, T. K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[15] Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [J].

DePrimo, Samuel E. ;

Bello, Carlo L. ;

Smeraglia, John ;

Baum, Charles M. ;

Spinella, Dominic ;

Rini, Brian I. ;

Michaelson, M. Dror ;

Motzer, Robert J. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5

[16] Tissue Biomarkers in Renal Cell Carcinoma: Issues and Solutions [J].

Di Napoli, Arianna ;

Signoretti, Sabina .

CANCER, 2009, 115 (10) :2290-2297

[17] Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Staehler, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Anderson, Sibyl ;

Hofilena, Gloria ;

Shan, Minghua ;

Pena, Carol ;

Lathia, Chetan ;

Bukowski, Ronald M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318

[18] Analysis of PTEN and HIF-1α and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-α [J].

Figlin, Robert A. ;

de Souza, Paul ;

McDermott, David ;

Dutcher, Janice P. ;

Berkenblit, Anna ;

Thiele, Alexandra ;

Krygowski, Mizue ;

Strahs, Andrew ;

Feingold, Jay ;

Boni, Joseph ;

Hudes, Gary .

CANCER, 2009, 115 (16) :3651-3660

[19] MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy [J].

Finke, James ;

Ko, Jennifer ;

Rini, Brian ;

Rayman, Pat ;

Ireland, Joanna ;

Cohen, Peter .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (07) :856-861

[20] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J].

Gerlinger, Marco ;

Rowan, Andrew J. ;

Horswell, Stuart ;

Larkin, James ;

Endesfelder, David ;

Gronroos, Eva ;

Martinez, Pierre ;

Matthews, Nicholas ;

Stewart, Aengus ;

Tarpey, Patrick ;

Varela, Ignacio ;

Phillimore, Benjamin ;

Begum, Sharmin ;

McDonald, Neil Q. ;

Butler, Adam ;

Jones, David ;

Raine, Keiran ;

Latimer, Calli ;

Santos, Claudio R. ;

Nohadani, Mahrokh ;

Eklund, Aron C. ;

Spencer-Dene, Bradley ;

Clark, Graham ;

Pickering, Lisa ;

Stamp, Gordon ;

Gore, Martin ;

Szallasi, Zoltan ;

Downward, Julian ;

Futreal, P. Andrew ;

Swanton, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) :883-892

← 1 2 3 4 5 6 →